Manufacture of recombinant polyclonal antibodies.
Polyclonal antibody therapy in the form of hyper-immune serum has for more than a century been used for treatment of many infectious diseases. However, with the emergence of first antibiotics and later recombinant monoclonal antibody therapy, the use of hyper-immune serum has declined. The main reason for this is that methods for consistent manufacturing of safe hyper immune immunoglobulin products have been lacking. In contrast, manufacturing processes of recombinant monoclonal antibodies follow a well established schedule and it appears obvious to use similar methods to produce recombinant polyclonal products. However, the methods for monoclonal antibody manufacturing are, for several reasons, not directly applicable to generation and manufacture of polyclonal recombinant antibodies. A new production strategy based on recombinant mammalian producer cells has recently been developed to support consistent generation of recombinant polyclonal antibodies for therapeutic use. This review describes aspects of this novel technology with emphasis on the generation, production and characterization procedures employed, and provides comparison with alternative polyclonal and monoclonal antibody manufacturing strategies.
Rasmussen
S K
SK
Symphogen A/S, Electrovej, Lyngby, Denmark.
Rasmussen
L K
LK
Weilguny
D
D
Tolstrup
A B
AB
D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis* / Q000235:genetics / Q000276:immunology; D006801:Humans; D007106:Immune Sera / Q000276:immunology; D018448:Models, Immunological; D011994:Recombinant Proteins / Q000096:biosynthesis* / Q000276:immunology; D012204:Rh-Hr Blood-Group System / Q000235:genetics / Q000276:immunology
D000911:Antibodies, Monoclonal; D007106:Immune Sera; D011994:Recombinant Proteins; D012204:Rh-Hr Blood-Group System; C026410:Rho(D) antigen